Reports of suspected adverse reactions to COVID-19 vaccines in Switzerland – update 28

25.11.2022

Reporting period 01.01.2021–22.11.2022

16,212 reports of suspected adverse reactions evaluated – the overall positive benefit-risk ratio of the vaccines remains

Up to 22 November 2022, Swissmedic evaluated 16,212 reports on suspected adverse drug reactions (ADRs).

10,013 (61.8 %) were reported to Swissmedic as “not serious”, while 6,199 suspected cases (38.2%) were classified as «serious».1 The majority of the reports involved more than one reaction. In total, 50, 528 reactions were reported, corresponding to an average of 3.12 reactions per report.

The reporting individuals themselves defined whether they classified the cases as serious or not serious. According to international pharmacovigilance practice, this categorisation is revised only for events that were reported as not serious if the ADR is subsequently classified as serious on the basis of further information.

Reports

16,212

Not serious

10,013 (61,8 %)

Reporting rate

0.97

Serious

6,199 (38.2 %)

Vaccine doses

16 734 858

Vaccinated people

6 116 442

Primary reporter
The Therapeutic Products Act (TPA) requires healthcare professionals to report serious adverse effects and as yet unknown effects to Swissmedic. 7,246 (45%) reports were submitted by healthcare professionals. Members of the public may voluntarily report suspected side effects of medicines: 8,932 reports (55%) were received directly from those affected, i.e. the patients, or their relatives.

Age and gender of persons affected
Most of those affected (67.1 %) were aged between 18 and 64 years (50.2 years on average). 19.7 % of the individuals were older than 65, while 1.1 % were 12 to 17 years old.

9,042 (62.1 %) of the reports concerned women, 5,683 (35.1%) of the reports concerned men. In a few reports no age or gender was specified.

Evaluations of individual vaccines

11,187 (69%) of the reports involve Moderna’s COVID-19 vaccine Spikevax® (with approx. 63% of the vaccine doses administered, this is the most widely used vaccine in Switzerland) while 4,535 (28%) are associated with Pfizer/BioNTech’s Comirnaty® (approx. 37 % of administered vaccine doses). In some cases, the vaccine was not specified.

Number of reports by vaccine and dose

Vaccine

Total reports

of which non-serious

of which serious

Total vaccine doses * [2]

Spikevax® (Moderna) [1]

8,822 (54.4 %)

5,701 (56.9 %)

3,121 (50.4 %)

10,519,274 (62.9 %)

Spikevax® (Moderna) 3rd vaccination

2,263 (14.0%)

1,611 (16.1 %)

652 (10.5 %)

Spikevax® (Moderna) 4th vaccination

50 (0.3 %)

28 (0.3 %)

22 (0.4 %)

Spikevax® (Moderna) 5th vaccination

1 (0.0 %)

1 (0.0 %)

0 (0.0 %)

Spikevax® (Moderna) Bivalent Original / Omicron BA.1

51 (0.3%)

35 (0.4 %)

16 (0.3 %)

Comirnaty® (Pfizer/BioNTech) [1]

4,021 (24.8 %)

2,123 (21.2 %)

1,898 (30.6 %)

6,134,245 (36.7 %)

 

Comirnaty® (Pfizer/BioNTech) 3rd vaccination

489 (3,0 %)

274 (2.7 %)

215 (3.5 %)

Comirnaty® (Pfizer/BioNTech) 4th vaccination

21 (0.1 %)

9 (0.1)

12 (0.0)

Comirnaty® (Pfizer/BioNTech) Bivalent Original / Omicron BA.1

4 (0.0)

2 (0.0)

2 (0.0)

COVID-19 Vaccine Janssen [1]

157 (1.0 %)

81 (0.8 %)

76 (1.2 %)

63,369 (0.4 %)

Nuvaxovid® (Novavax)

1 (0.0)

0 (0.0 %)

1 (0.0 %)

2,356 (0.0 %)

Unknown [1]

299 (1,8 %)

129 (1,3 %)

170 (2,7 %)

 

Unknown [2]

33 (0,2 %)

19 (0,2 %)

14 (0,2 %)

 

Total

16,212 (100 %)

10,013 (100 %)

6,199 (100 %)

16,734,858 (100 %)

[1] Basic immunisation (two doses)

[2] Basic immunisation (two doses), booster and bivalent vaccines

* Switzerland and Principality of Liechtenstein, 21.12.2020–21.11.2022 (Source: FOPH)

Reports classified as serious

Around 38 % of cases were classified by the reporters as serious. In these reports, the average age of those affected was 52.7. The most commonly reported reactions were fever, headache, fatigue, shivering, nausea and dizziness. These known reactions also predominated in the cases classified as not serious.

In 227 of the serious cases, a fatality was reported at differing intervals after receiving the vaccine. The average age of those who died was 78.8 years. Despite a temporal association, an in-depth analysis of the data available for these cases showed that there were other more likely causes of the reported deaths.

Reported vaccine reactions and affected organ systems by vaccine


The reports of adverse reactions received and analysed to date do not alter the positive benefit-risk profile of the COVID-19 vaccines used in Switzerland. This largely confirms their known side effects profile. Known side effects of COVID-19 vaccines are listed in the continually updated medicinal product information texts published on www.swissmedicinfo.ch.

The reports of suspected adverse drug reactions (ADR) to COVID-19 vaccinations are evaluated in collaboration with the regional pharmacovigilance centres and in particular with the Ticino reference centre (EOC cantonal hospital authority).

The next update on reports of suspected adverse reactions to COVID-19 vaccines in Switzerland is expected to be published at the end of February 2023.
You can find the latest report on at the following permalink: www.swissmedic.ch/covid-19-vaccines-safety-update-en

Information from Swissmedic on individual safety aspects

Myocarditis / pericarditis

Very rare cases of myocarditis and pericarditis (inflammation of the heart muscle/pericardium) have been reported following vaccination with the COVID-19 mRNA vaccines. Cases generally occur within 14 days of vaccination and more frequently after the second dose and in younger men.

Healthcare professionals should pay attention to the signs and symptoms of myocarditis and pericarditis and inform vaccinated people that they should seek immediate medical advice and assistance in the event of chest pains, shortness of breath or palpitations. Strong physical exertion should be avoided if such symptoms occur until the cause of the symptoms has been ascertained.

By 22 November 2022, 416 cases of myocarditis and/or pericarditis with a suspected link to vaccinations had been reported in Switzerland and evaluated out of a total of around 16.7 million vaccine doses administered. Of these, 94 were linked chronologically with Comirnaty (18 of which were after the third dose) and 306 with Spikevax (25 of which were after the third dose); in 12 cases, the vaccine has not yet been identified, while 4 cases concerned the COVID-19 vaccine from Janssen. The large majority of cases involved males (n = 300, 72.11 %), and the mean age was 36.64 years (median 34, range 14 to 88 years). The persons affected received medical treatment and most have now recovered. There is currently no indication that the number of reports of myocarditis and/or pericarditis is increasing following booster shots/third vaccinations.

Various studies have shown that inflammation of the heart muscle and heart sac in those under 30 years of age is observed more frequently after vaccination with Spikevax than after vaccination with Comirnaty. Newly published data will be analysed continuously and, if necessary, the vaccination recommendation for mRNA vaccines against COVID-19 will be reviewed by the Federal Commission for Vaccination (FCV).

Reports after vaccination with a bivalent vaccine

55 reports of adverse effects after vaccination with a bivalent vaccine were received (Spikevax bivalent Original/Omicron or Comirnaty bivalent), 18 (33%) of which were classified as serious. The most frequently reported adverse effects were headache, fever, joint pain and nausea.

Reports of menstrual disorders

Since the start of vaccinations against COVID-19, Swissmedic has received around 600 reports of various forms of menstrual disorders, the most frequent being cases of heavy menstrual bleeding. Based on these reports and available study results on this, inclusion of these reactions in the product information of mRNA vaccines against COVID-19 is currently being considered.

Reporting a general adverse reaction to a medicinal product or a suspected adverse reaction in connection with a COVID-19 vaccine

Private individuals can now submit all reports of suspected adverse reactions to human medicinal products to Swissmedic via a web form. You can report an adverse drug reaction for yourself or on behalf of another person, such as a child or relative.

Previous reports

26.08.2022

Reports of suspected adverse reactions to COVID-19 vaccines

15,781 reports of suspected adverse vaccination reactions evaluated

01.07.2022

Reports of suspected adverse reactions to COVID-19 vaccines

15,578 reports of suspected adverse vaccination reactions evaluated

06.05.2022

Reports of suspected adverse reactions to COVID-19 vaccines

15,228 reports of suspected adverse vaccination reactions evaluated

08.04.2022

Reports of suspected adverse reactions to COVID-19 vaccines

14,624 reports of suspected adverse vaccination reactions evaluated

11.03.2022

Reports of suspected adverse reactions to COVID-19 vaccines

13,388 reports of suspected adverse vaccination reactions evaluated

11.02.2022

Reports of suspected adverse reactions to COVID-19 vaccines

12,334 reports of suspected adverse vaccination reactions evaluated

14.01.2022

Reports of suspected adverse reactions to COVID-19 vaccines

11,467 reports of suspected adverse vaccination reactions evaluated

17.12.2021

Reports of suspected adverse reactions to COVID-19 vaccines

10,842 reports of suspected adverse vaccination reactions evaluated

26.11.2021

Reports of suspected adverse reactions to COVID-19 vaccines

10,386 reports of suspected adverse vaccination reactions evaluated

05.11.2021

Reports of suspected adverse reactions to COVID-19 vaccines

9,834 reports of suspected adverse vaccination reactions evaluated

15.10.2021

Reports of suspected adverse reactions to COVID-19 vaccines

8,757 reports of suspected adverse vaccination reactions (ADR) evaluated – the overall positive benefit-risk ratio of the vaccines remains

24.09.2021

Reports of suspected adverse reactions to COVID-19 vaccines

7,571 reports evaluated – the overall positive benefit-risk ratio of the vaccines remains

03.09.2021

Reports of suspected adverse reactions to COVID-19 vaccines

6,603 reports evaluated – the overall positive benefit-risk ratio of the vaccines remains

13.08.2021

Reports of suspected adverse reactions to COVID-19 vaccines in Switzerland – update

5,304 reports evaluated – the overall positive benefit-risk ratio of the vaccines remains

23.07.2021

Reports of suspected adverse reactions to COVID-19 vaccines in Switzerland – update

4,319 reports evaluated – the overall positive benefit-risk ratio of the vaccines remains

02.07.2021

Reports of suspected adverse reactions to COVID-19 vaccines in Switzerland – update

3,419 reports evaluated – the overall positive benefit-risk ratio of the vaccines remains

18.06.2021

Reports of suspected adverse reactions to COVID-19 vaccines in Switzerland – update

2,944 reports evaluated – the overall positive benefit-risk ratio of the vaccines remains

04.06.2021

Side effects of COVID-19 vaccines in Switzerland – update

2,701 reports of suspected adverse reactions to COVID-19 vaccines in Switzerland evaluated

21.05.2021

Side effects of COVID-19 vaccines in Switzerland – update

2269 reports of suspected adverse reactions to COVID-19 vaccines in Switzerland evaluated

07.05.2021

Side effects of COVID-19 vaccines in Switzerland – update

1953 reports of suspected adverse reactions to COVID-19 vaccines in Switzerland evaluated

22.04.2021

Side effects of COVID-19 vaccines in Switzerland – update

1485 reports of suspected adverse reactions to COVID-19 vaccines in Switzerland evaluated

09.04.2021

Side effects of COVID-19 vaccines in Switzerland – update

1174 reports of suspected adverse reactions to COVID-19 vaccines in Switzerland evaluated

11.03.2021

Side effects of COVID-19 vaccines in Switzerland – update

597 reports of suspected adverse reactions to COVID-19 vaccines in Switzerland evaluated

26.02.2021

Side effects of COVID-19 vaccines in Switzerland – update

364 reports of suspected adverse reactions to COVID-19 vaccines in Switzerland evaluated

05.02.2021

Reports of suspected adverse reactions to the COVID-19 vaccines in Switzerland – Update

To date, 63 side effect reports in connection with COVID-19 vaccinations in Switzerland have been evaluated

22.01.2021

Reports of suspected adverse reactions to the COVID-19 vaccines in Switzerland

Reports to date in line with the known risk profile

Supplementary information

Guide to interpreting the data

Given the methodology of the spontaneous reporting system, the following factors need to be taken into account when interpreting the data presented here:

  • The figures provided relate to suspected reactions reported to Swissmedic and entered in the database after being reviewed.
  • All the reactions reported are suspected cases. In individual cases it has not been ascertained whether the reported reaction was only observed in a temporal relationship with the vaccination or was actually caused by it.
  • The number of suspected cases for each vaccine can depend greatly on how many people received this vaccine in the period in question.The nu mber of vaccination reactions could be higher than the number of reports. Depending on the authorised use (e.g. age group, high-risk individual) and the latest vac cination recommendations, certain vaccines are more frequently administered to people with a serious preexisting condition.
  • This can influence the occurrence of certain reactions which, however, are only indirectly related to the particular vaccine.
  • The figures for suspected cases of vaccination reactions are just one of many elements used to monitor the risk-benefit profile of vaccines. Only a detailed scientific evaluation of all the available data will enable the correct conclusions to be made about a vaccine’s safety profile.